A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators

Molecular Pharmacology

Volumn 70, Issue 2, 2006, Pages 616-626

  Hemstapat, Kamondanai ^a   De Paulis, Tomas ^a   Chen, Yelin ^a   Brady, Ashley E ^a   Grover, Vandana K ^a   Alagille, David ^b   Tamagnan, Gilles D ^b   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIHYDRO 2H PYRANO[2,3 B]QUINOLIN 7 YL) 2 PHENYL 1 ETHANONE; 2 (FLUOROPHENYL) 1 (TOLUENE 4 SULFONYL)PYRROLIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 4 NITRO N (1,4 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; BENZAMIDE DERIVATIVE; BUTYL (9H XANTHENE 9 CARBONYL)CARBAMATE; CARBAMIC ACID DERIVATIVE; ETHYL DIPHENYLACETYLCARBAMATE; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; R 214127; RADIOLIGAND; RO 016128; RO 674583; RO 677476; UNCLASSIFIED DRUG; VALINE; VU 34; VU 48; VU 54; VU 60; VU 71;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BENZAMIDES; CALCIUM; CELLS, CULTURED; CRICETINAE; PYRAZOLES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746265808     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.021857     Document Type: Article

References (36)

1. Adwanikar H, Karim F, and Gereau RW (2004) Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain 111:125-135.
2. Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, and Bristow LJ (2004) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 175:310-318.
3. Chen Y, de Paulis T, Hemstapat K, and Conn PJ (2005) Novel allosteric potentiators of mGluR5 act through binding to the same site as that of MPEP, a related allosteric antagonist. Neuropharmacology 49 (Suppl 1):238.
4. Conn PJ (2003) Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann NY Acad Sci 1003:12-21.
5. Conn PJ, Battaglia G, Marino MJ, and Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6:787-798.
6. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
7. de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, and Conn PJ (2006) Substituent effects of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 49:3332-3344.
8. Epping-Jordan MP, Nayak S, Derouet F, Dominguez H, Bessis AS, Le Poul E, Ludwig B, Mutel V, Poli SM, and Rocher JP (2005) In vivo characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction. Neuropharmacol 49 (Suppl 1):243.
9. Fisher K, Lefebvre C, and Coderre TJ (2002) Antinociceptive effects following intrathecal pretreatment with selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol Biochem Behav 73:411-418.
10. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
11. Gasparini F, Kuhn R, and Pin JP (2002) Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2:43-49.
12. Grinnell BW, Walls JD, and Gerlitz B (1991) Glycosylation of human protein C affects its secretion, processing, functional activities and activation by thrombin. J Biol Chem 266:9778-9785.
13. Kew JNC (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 104:233-244.
14. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206.
15. Knoflach F, Mutel V, Kew JNC, Malherbe P, Vieira E, Wichmann J, and Kemp JA (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc Natl Acad Sci USA 98:13402-13407.
16. Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, Hayashibe S, Kawabata S, and Okada M (2005) Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3, 2-α]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective and non-competitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther 315:163-169.
17. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63:1082-1093.
18. Lindsley CW, Wisnoski DD, Leister WH, O'Brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, et al. (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 47:5825-5828.
19. Litschig S, Gasparini F, Ruegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
20. Mabire D, Coupa S, Adelinet C, Poncelet A, Simonnet Y, Venet M, Wouters R, Lesage ASJ, Van Beijsterveldt L, and Bischoff F (2005) Synthesis, structure-activity relationships and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGluR1 antagonists. J Med Chem 48:2134-2153.
21. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, et al. (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action and neuroprotection. Neuropharmacology 45:895-906.
22. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, Maerki HP, Adam G, and Mutel V (2003) Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 278:8340-8347.
23. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, et al. (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 100:13668-13673.
24. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, and Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030.
25. Moghaddam B (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44.
26. Nagaraja RY, Becker A, Reymann KG, and Balschun D (2005) Repeated administration of group I mGluR antagonists prevents seizure-induced long-term aberrations in hippocampal synaptic plasticity. Neuropharmacology 49 (Suppl 1):179-187.
27. O'Brien JA, Lemaire W, Chen TB, Chang RSL, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, et al. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 64:731-740.
28. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577.
29. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin JP, et al. (2000) The noncompetitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyimino-cyclopropan[b] chromen-1α-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
30. Peavy RD, Chang MSS, Sanders-Bush E, and Conn PJ (2001) Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J Neurosci 21:9619-9628.
31. Rasmussen K, Martin H, Berger JE, and Seager MA (2005) The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology 48:173-180.
32. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, and Conn PJ (2005) A close structural analog of MPEP acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802.
33. Roppe JR, Wang B, Huang D, Tehrani L, Kamenecka T, Schweiger EJ, Anderson JJ, Brodkin J, Jiang X, Cramer M, et al. (2004) 5-[(2-Methyl-1,3-thiazol-4-yl) ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg Med Chem Lett 14:3993-3996.
34. Schoepp DD, Jane DE, and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476.
35. Tessari M, Pilla M, Andreoli M, Hutcheson DM, and Heidbreder CA (2004) Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 499:121-133.
36. Zheng GZ, Bhatia P, Daanen J, Kolasa T, Patel M, Latshaw S, El Kouhen OF, Chang R, Uchic ME, Miller L, et al. (2005) Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem 48:7374-7388.